p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies
Cytotoxic chemotherapy for acute myeloid leukemia (AML) usually produces only temporary
remissions, at the cost of significant toxicity and risk for death. One fundamental reason for
treatment failure is that it is designed to activate apoptosis genes (eg, TP53) that may be
unavailable because of mutation or deletion. Unlike deletion of apoptosis genes, genes that
mediate cell cycle exit by differentiation are present in myelodysplastic syndrome (MDS) and
AML cells but are epigenetically repressed: MDS/AML cells express high levels of key …
remissions, at the cost of significant toxicity and risk for death. One fundamental reason for
treatment failure is that it is designed to activate apoptosis genes (eg, TP53) that may be
unavailable because of mutation or deletion. Unlike deletion of apoptosis genes, genes that
mediate cell cycle exit by differentiation are present in myelodysplastic syndrome (MDS) and
AML cells but are epigenetically repressed: MDS/AML cells express high levels of key …